Form 8-K - Current report:
SEC Accession No. 0001641172-25-019856
Filing Date
2025-07-16
Accepted
2025-07-16 12:40:52
Documents
12
Period of Report
2025-07-15
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 40374
  Complete submission text file 0001641172-25-019856.txt   206144

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE zvsa-20250715.xsd EX-101.SCH 3011
3 XBRL LABEL FILE zvsa-20250715_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE zvsa-20250715_pre.xml EX-101.PRE 22356
14 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3699
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41184 | Film No.: 251126749
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)